Masatoshi Kudo Selected Research

Hepatocellular Carcinoma (Hepatoma)

10/2022	Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study.
9/2022	Impact of bodyweight-based starting doses on the safety and efficacy of lenvatinib in primarily Japanese patients with hepatocellular carcinoma.
9/2022	Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice.
7/2022	New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma.
6/2022	Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib.
6/2022	A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors.
5/2022	Performance evaluation of the Elecsys PIVKA-II and Elecsys AFP assays for hepatocellular carcinoma diagnosis.
4/2022	Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma.
4/2022	Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.
4/2022	Response Evaluation Criteria in Cancer of the liver version 6 (Response Evaluation Criteria in Cancer of the Liver 2021 revised version).

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Masatoshi Kudo Research Topics

Disease

371	Hepatocellular Carcinoma (Hepatoma) 10/2022 - 11/2001
179	Neoplasms (Cancer) 06/2022 - 11/2001
46	Liver Neoplasms (Liver Cancer) 01/2022 - 01/2003
31	Neoplasm Metastasis (Metastasis) 04/2022 - 11/2001
28	Fibrosis (Cirrhosis) 10/2022 - 12/2005
26	Infections 08/2021 - 01/2004
25	Chronic Hepatitis C 08/2019 - 01/2002
23	Liver Diseases (Liver Disease) 11/2021 - 01/2003
22	Inflammation (Inflammations) 04/2022 - 10/2002
19	Hypertension (High Blood Pressure) 03/2022 - 10/2013
18	Disease Progression 01/2022 - 01/2011
16	Pancreatic Neoplasms (Pancreatic Cancer) 05/2022 - 01/2006
15	Immunoglobulin G4-Related Disease 05/2021 - 03/2012
15	Liver Cirrhosis (Hepatic Cirrhosis) 07/2019 - 10/2005
14	Fatigue 06/2022 - 09/2013
13	Hepatitis 01/2022 - 01/2003
12	Autoimmune Pancreatitis 05/2021 - 02/2010
12	Hepatitis C 06/2017 - 12/2006
11	Hemorrhage 06/2021 - 02/2002
11	Ascites 06/2021 - 02/2006
11	Hepatitis B 11/2020 - 10/2006
11	Chronic Hepatitis (Chronic Active Hepatitis) 01/2011 - 01/2002
10	Chronic Hepatitis B 09/2022 - 01/2011
10	Pancreatitis 04/2022 - 01/2009
10	Ulcerative Colitis 01/2022 - 11/2006
9	Necrosis 04/2022 - 07/2010
9	Carcinogenesis 01/2019 - 01/2011
7	Cholangitis 01/2022 - 01/2011
7	Thrombocytopenia (Thrombopenia) 02/2019 - 12/2010
6	Colitis 12/2022 - 01/2019
6	Pathologic Constriction (Stenosis) 01/2022 - 11/2016
6	Thrombosis (Thrombus) 01/2022 - 01/2003
6	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2021 - 01/2015
6	Ulcer 08/2020 - 09/2009
5	Diarrhea 06/2022 - 01/2016
5	COVID-19 01/2022 - 09/2020
5	Autoimmune Hepatitis 08/2021 - 02/2010
5	Pain (Aches) 01/2021 - 01/2011
5	Stomach Neoplasms (Stomach Cancer) 09/2019 - 09/2009
5	Adenocarcinoma 07/2019 - 01/2004

Drug/Important Bio-Agent (IBA)

95	Sorafenib (BAY 43-9006)FDA Link 07/2022 - 06/2010
42	InterferonsIBA 07/2021 - 01/2002
38	lenvatinibIBA 09/2022 - 01/2017
32	Immune Checkpoint InhibitorsIBA 09/2022 - 01/2016
30	Biomarkers (Surrogate Marker)IBA 06/2022 - 11/2006
25	RamucirumabIBA 07/2022 - 07/2015
22	Proteins (Proteins, Gene)FDA Link 07/2022 - 04/2002
22	alpha-Fetoproteins (alpha-Fetoprotein)IBA 05/2022 - 12/2006
19	Immunoglobulin G (IgG)IBA 06/2021 - 02/2010
19	SonazoidIBA 01/2021 - 01/2008
19	Ribavirin (Virazole)FDA LinkGeneric 01/2017 - 01/2008
18	BilirubinIBA 01/2022 - 02/2006
18	gadolinium ethoxybenzyl DTPA FDA Link 11/2021 - 01/2009
16	AlbuminsIBA 01/2022 - 01/2011
15	Bevacizumab (Avastin)FDA Link 10/2022 - 01/2019
15	CytokinesIBA 01/2022 - 11/2006
14	atezolizumabIBA 10/2022 - 01/2020
14	Pharmaceutical PreparationsIBA 01/2022 - 11/2009
13	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 07/2010
13	Antiviral Agents (Antivirals)IBA 10/2019 - 01/2011
13	Contrast MediaIBA 04/2017 - 11/2001
12	LigandsIBA 07/2022 - 03/2012
12	Tumor Biomarkers (Tumor Markers)IBA 10/2019 - 10/2005
11	acarboxyprothrombin (PIVKA)IBA 05/2022 - 12/2006
11	pembrolizumabIBA 04/2022 - 01/2017
11	Hepatitis B Surface Antigens (HBsAg)FDA Link 12/2021 - 10/2006
11	Interleukin-33IBA 05/2021 - 01/2017
10	NivolumabIBA 01/2022 - 01/2017
9	DNA (Deoxyribonucleic Acid)IBA 12/2021 - 01/2011
9	Fetal Proteins (Fetoprotein)IBA 07/2021 - 09/2007
9	AntigensIBA 01/2021 - 01/2008
8	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2022 - 12/2010
8	GadoliniumIBA 11/2021 - 01/2011
8	Coloring Agents (Dyes)IBA 01/2020 - 12/2002
8	SHU 508 (Levovist)IBA 07/2010 - 11/2001
7	entecavir FDA Link 12/2021 - 08/2011
7	Serum AlbuminIBA 08/2021 - 02/2006
7	NucleotidesIBA 01/2021 - 10/2002
7	Alanine Transaminase (SGPT)IBA 01/2020 - 01/2008
7	RNA (Ribonucleic Acid)IBA 01/2017 - 01/2002
6	regorafenibIBA 07/2022 - 01/2016
6	EnzymesIBA 04/2022 - 10/2011
6	CateninsIBA 01/2022 - 05/2014
6	Tyrosine Kinase InhibitorsIBA 06/2021 - 01/2011
6	Pentetic Acid (DTPA)FDA LinkGeneric 01/2017 - 04/2011
5	AntibodiesIBA 04/2020 - 01/2017
5	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2020 - 10/2013

Therapy/Procedure

190	Therapeutics 07/2022 - 01/2002
63	Radiofrequency Ablation 04/2022 - 01/2003
26	Drug Therapy (Chemotherapy) 01/2022 - 01/2009
17	Immunotherapy 04/2022 - 03/2018
14	Stents 01/2022 - 01/2011
12	Aftercare (After-Treatment) 01/2018 - 03/2003
11	Molecular Targeted Therapy 09/2019 - 01/2008
10	Hepatectomy 01/2022 - 03/2002
9	Microbubbles 05/2010 - 11/2001
8	Surgical Instruments (Clip) 06/2021 - 01/2003
6	Electrodes (Electrode) 10/2016 - 07/2004
5	Sclerotherapy 01/2020 - 01/2004
5	Liver Transplantation 09/2018 - 01/2007